Mechanism of inhibition of platelet aggregation by HCL-31D

被引：10

作者：

Chou, TC

Li, CY

Lee, AR

Wu, TM

机构：

[1] Natl Taiwan Normal Univ, Natl Def Med Ctr, TriServ Gen Hosp, Grad Inst Med Sci, Taipei, Taiwan

[2] Natl Taiwan Normal Univ, Natl Def Med Ctr, TriServ Gen Hosp, Dept Anesthesiol, Taipei, Taiwan

[3] Natl Taiwan Normal Univ, Natl Def Med Ctr, TriServ Gen Hosp, Dept Pharm, Taipei, Taiwan

[4] Natl Taiwan Normal Univ, Natl Def Med Ctr, TriServ Gen Hosp, Dept Biol, Taipei, Taiwan

来源：

EUROPEAN JOURNAL OF PHARMACOLOGY | 2000年 / 387卷 / 02期

关键词：

HCL-31D; platelet aggregation; cAMP; thromboxane B-2; phosphoinositide breakdown;

D O I：

10.1016/S0014-2999(99)00812-2

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The antiplatelet effect of the pyridazinone analogue, 4,5-dihydro-6-[4-[2-hydroxy-3-(3,4 dimethoxybenzylamino)propoxy]naphth- 1-yl]- 3(2H)-pyridazinone (HCL-31D), was investigated in vitro with rabbit platelets. HCL-31D dose-dependently inhibited the platelet aggregation and ATP release induced by collagen (10 mu g/ml), arachidonic acid (100 mu M) or thrombin (0.1 U/ml) with an IC50 of about 0.95-5.41 mu M. HCL-31D (0.5-5 mu M) increased the platelet cyclic AMP level in a dose-dependent manner. Furthermore, HCL-31D potentiated cyclic AMP formation caused by prostaglandin E-1 but not that caused by 3-isobutyl-1-methylxanthine (IBMX). HCL-31D also attenuated phosphoinositide breakdown and intracellular Ca2+ elevation induced by collagen, arachidonic acid or thrombin. HCL-31D inhibited the formation of thromboxane B-2 induced by collagen or thrombin but not by arachidonic acid. In addition, HCL-31D did not affect platelet cylooxygenase and thromboxane synthase activity. These data indicate that HCL-SID is an inhibitor of phosphodiesterase and that its antiplatelet effect is mainly mediated by elevation of cyclic AMP levels. (C) 2000 Elsevier Science B.V. All rights reserved.

引用

页码：125 / 131

页数：7

共 33 条

[1] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].

ALTMAN, R ;

CARRERAS, L ;

DIAZ, R ;

FIGUEROA, E ;

PAOLASSO, E ;

PARODI, JC ;

CADE, JF ;

DONNAN, G ;

EADIE, MJ ;

GAVAGHAN, TP ;

OSULLIVAN, EF ;

PARKIN, D ;

RENNY, JTG ;

SILAGY, C ;

VINAZZER, H ;

ZEKERT, F ;

ADRIAENSEN, H ;

BERTRANDHARDY, JM ;

BRAN, M ;

DAVID, JL ;

DRICOT, J ;

LAVENNEPARDONGE, E ;

LIMET, R ;

LOWENTHAL, A ;

MORIAU, M ;

SCHAPIRA, S ;

SMETS, P ;

SYMOENS, J ;

VERHAEGHE, R ;

VERSTRAETE, M ;

ATALLAH, A ;

BARNETT, H ;

BATISTA, R ;

BLAKELY, J ;

CAIRNS, JA ;

COTE, R ;

CROUCH, J ;

EVANS, G ;

FINDLAY, JM ;

GENT, M ;

LANGLOIS, Y ;

LECLERC, J ;

NORRIS, J ;

PINEO, GF ;

POWERS, PJ ;

ROBERTS, R ;

SCHWARTZ, L ;

SICURELLA, J ;

TAYLOR, W ;

THEROUX, P .

BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100

[2]

BELL RL, 1979, P NATL ACAD SCI USA, V76, P1790

[3]

BENJAMIN CW, 1993, J PHARMACOL EXP THER, V265, P457

[4] INOSITOL TRISPHOSPHATE AND DIACYLGLYCEROL AS 2ND MESSENGERS [J].

BERRIDGE, MJ .

BIOCHEMICAL JOURNAL, 1984, 220 (02) :345-360

[5]

BILLAH MM, 1981, J BIOL CHEM, V256, P5399

[6] Phosphodiesterase inhibitors piroximone and enoximone inhibit platelet aggregation in vivo and in vitro [J].

Buerke, M ;

Cyrus, T ;

Darius, H .

THROMBOSIS RESEARCH, 1997, 88 (02) :89-98

[7] The inhibitory effect of 2-thienyl 2'-hydroxyphenyl ketone (C85) on platelet thromboxane formation [J].

Chou, TC ;

Hsu, LY ;

Yen, MH ;

Ding, YA .

THROMBOSIS RESEARCH, 1996, 84 (02) :83-95

[8]

DeLuca M., 1978, METHOD ENZYMOL, V57, P3, DOI DOI 10.1016/0076-6879(78)57003-1

[9] STIMULATION OF THE 23-KD PROTEIN CAMP DEPENDENT PHOSPHORYLATION BY INOSITOL 1,4,5 TRISPHOSPHATE IN HUMAN-PLATELET MEMBRANE-VESICLES [J].

ENOUF, J ;

GIRAUD, F ;

BREDOUX, R ;

BOURDEAU, N ;

LEVYTOLEDANO, S .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1987, 145 (01) :139-145

[10]

FEINSTEIN MB, 1985, PLATELETS PHYSL PHAR, P237

← 1 2 3 4 →